Regenerative Medical Technology (RMTG) FCF Margin (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly FCF Margin of 8.08% for Q1 2026, down 1227.0% year-over-year from 0.72% in Q1 2025, and up 44.53% quarter-over-quarter from 14.57% in Q4 2025.
Regenerative Medical Technology (RMTG) FCF Margin (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's FCF Margin history runs 9 years deep, the most recent figure standing at 8.08% for Q1 2026.
- In Q1 2026, FCF Margin fell 1227.0% year-over-year to 8.08%; the TTM figure through Mar 2026 stood at 23.04% (down 3687.0% YoY), while the FY2025 annual figure was 25.67%, down 4113.0% from the prior year.
- FCF Margin for Q1 2026 stood at 8.08%, up from 14.57% in the prior quarter.
- The five-year high for FCF Margin was 22.24% in Q3 2024, with the low at 172.78% in Q1 2022.
- The 5-year median for FCF Margin is 14.57% (2025), against an average of 35.68%.
- The sharpest annual moves came in 2022 and 2025: FCF Margin soared 343700 bps in 2022, then plunged 6557 bps in 2025.
- Regenerative Medical Technology's FCF Margin stood at 20.83% in 2022, then slumped by 144 bps to 50.91% in 2023, then soared by 143 bps to 21.8% in 2024, then sank by 167 bps to 14.57% in 2025, then surged by 45 bps to 8.08% in 2026.
- Business Quant data shows RMTG's FCF Margin at 8.08% in Q1 2026, 14.57% in Q4 2025, and 36.3% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Regenerative Medical Technology | 961,772.49 | -99,675.51 | 1.77 Mn | -8.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.08% |
| Dec 31, 2025 | -14.57% |
| Sep 30, 2025 | -36.30% |
| Jun 30, 2025 | -60.81% |
| Mar 31, 2025 | 4.19% |
| Dec 31, 2024 | 21.80% |
| Sep 30, 2024 | 22.24% |
| Jun 30, 2024 | 4.76% |
| Mar 31, 2024 | 5.97% |
| Dec 31, 2023 | -50.91% |
| Sep 30, 2023 | -12.56% |
| Jun 30, 2023 | -113.86% |
| Mar 31, 2023 | 0.16% |
| Dec 31, 2022 | -20.83% |
| Sep 30, 2022 | -41.73% |
| Jun 30, 2022 | -133.22% |
| Mar 31, 2022 | -172.78% |
| Dec 31, 2021 | -3,457.83% |
| Sep 30, 2021 | -260.94% |
| Jun 30, 2021 | -3,451.78% |